Jorge E. Cortes
University of Texas MD Anderson Cancer Center
Houston
TX 77030
USA
Name/email consistency: high
- Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Cortes, J., Lipton, J.H., Rea, D., Digumarti, R., Chuah, C., Nanda, N., Benichou, A.C., Craig, A.R., Michallet, M., Nicolini, F.E., Kantarjian, H. Blood (2012)
- How I treat newly diagnosed chronic phase CML. Cortes, J., Kantarjian, H. Blood (2012)
- Ponatinib in refractory Philadelphia chromosome-positive leukemias. Cortes, J.E., Kantarjian, H., Shah, N.P., Bixby, D., Mauro, M.J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N.I., Rivera, V.M., Clackson, T., Turner, C.D., Haluska, F.G., Druker, B.J., Deininger, M.W., Talpaz, M. N. Engl. J. Med. (2012)
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. Cortes, J.E., Kim, D.W., Kantarjian, H.M., Brümmendorf, T.H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A.M., Gambacorti-Passerini, C. J. Clin. Oncol. (2012)
- Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Pemmaraju, N., Kantarjian, H., Shan, J., Jabbour, E., Quintas-Cardama, A., Verstovsek, S., Ravandi, F., Wierda, W., O'Brien, S., Cortes, J. Haematologica (2012)
- Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cortes, J., Kantarjian, H., Ball, E.D., Dipersio, J., Kolitz, J.E., Fernandez, H.F., Goodman, M., Borthakur, G., Baer, M.R., Wetzler, M. Cancer (2012)
- Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia. Cortes, J.E. J. Clin. Oncol. (2012)
- Bosutinib for the treatment of chronic myeloid leukemia in chronic phase. Quintás-Cardama, A., Kantarjian, H., Cortes, J. Drugs. Today (2012)
- Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. Cortes, J., Hochhaus, A., Hughes, T., Kantarjian, H. J. Clin. Oncol. (2011)
- Monitoring molecular response in chronic myeloid leukemia. Cortes, J., Quintás-Cardama, A., Kantarjian, H.M. Cancer (2011)
- Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cortes, J., Quintás-Cardama, A., Jones, D., Ravandi, F., Garcia-Manero, G., Verstovsek, S., Koller, C., Hiteshew, J., Shan, J., O'Brien, S., Kantarjian, H. Cancer (2011)
- Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Quintás-Cardama, A., Kantarjian, H., O'Brien, S., Jabbour, E., Borthakur, G., Ravandi, F., Verstovsek, S., Shan, J., Cortes, J. Haematologica (2011)
- Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET). Cortes, J., De Souza, C., Ayala-Sanchez, M., Bendit, I., Best-Aguilera, C., Enrico, A., Hamerschlak, N., Pagnano, K., Pasquini, R., Meillon, L. Cancer (2010)
- Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. Cortes, J.E., Baccarani, M., Guilhot, F., Druker, B.J., Branford, S., Kim, D.W., Pane, F., Pasquini, R., Goldberg, S.L., Kalaycio, M., Moiraghi, B., Rowe, J.M., Tothova, E., De Souza, C., Rudoltz, M., Yu, R., Krahnke, T., Kantarjian, H.M., Radich, J.P., Hughes, T.P. J. Clin. Oncol. (2010)
- Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. Cortes, J.E., Jones, D., O'Brien, S., Jabbour, E., Konopleva, M., Ferrajoli, A., Kadia, T., Borthakur, G., Stigliano, D., Shan, J., Kantarjian, H. J. Clin. Oncol. (2010)
- Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. Cortes, J.E., Jones, D., O'Brien, S., Jabbour, E., Ravandi, F., Koller, C., Borthakur, G., Walker, B., Zhao, W., Shan, J., Kantarjian, H. J. Clin. Oncol. (2010)
- Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. Cortes, J., Moore, J.O., Maziarz, R.T., Wetzler, M., Craig, M., Matous, J., Luger, S., Dey, B.R., Schiller, G.J., Pham, D., Abboud, C.N., Krishnamurthy, M., Brown, A., Laadem, A., Seiter, K. J. Clin. Oncol. (2010)
- High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. Cortes, J.E., Kantarjian, H.M., Goldberg, S.L., Powell, B.L., Giles, F.J., Wetzler, M., Akard, L., Burke, J.M., Kerr, R., Saleh, M., Salvado, A., McDougall, K., Albitar, M., Radich, J. J. Clin. Oncol. (2009)
- Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? Quintás-Cardama, A., Cortes, J. Curr. Oncol. Rep (2009)
- Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Cortes, J.E., Egorin, M.J., Guilhot, F., Molimard, M., Mahon, F.X. Leukemia (2009)
- T-Cell acute lymphoblastic leukemia with a "pinch" of BCR-ABL1. Cortes, J., De Keersmaecker, K. Leuk. Lymphoma (2009)
- Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Cortes, J., Kim, D.W., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L., Coutre, S., Corm, S., Hamerschlak, N., Tang, J.L., Hochhaus, A., Khoury, H.J., Brümmendorf, T.H., Michallet, M., Rege-Cambrin, G., Gambacorti-Passerini, C., Radich, J.P., Ernst, T., Zhu, C., Van Tornout, J.M., Talpaz, M. Leukemia (2008)
- Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia. Cortes, J., Kantarjian, H. J. Natl. Compr. Canc. Netw (2008)
- Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Cortes, J., Jabbour, E., Kantarjian, H., Yin, C.C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., Wierda, W.G., Jones, D. Blood (2007)
- Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Cortes, J., Rousselot, P., Kim, D.W., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., Ottmann, O., Shah, N., Erben, P., Branford, S., Agarwal, P., Gollerkeri, A., Baccarani, M. Blood (2007)
- Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cortes, J., Jabbour, E., Daley, G.Q., O'Brien, S., Verstovsek, S., Ferrajoli, A., Koller, C., Zhu, Y., Statkevich, P., Kantarjian, H. Cancer (2007)
- Overcoming drug resistance in chronic myeloid leukemia. Cortes, J. Curr. Opin. Hematol. (2006)
- Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cortes, J.E., Talpaz, M., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Verstovsek, S., Rios, M.B., Shan, J., Kantarjian, H.M. Cancer (2006)
- Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. Cortes, J., Faderl, S., Estey, E., Kurzrock, R., Thomas, D., Beran, M., Garcia-Manero, G., Ferrajoli, A., Giles, F., Koller, C., O'Brien, S., Wright, J., Bai, S.A., Kantarjian, H. J. Clin. Oncol. (2005)
- Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Cortes, J., Talpaz, M., O'Brien, S., Jones, D., Luthra, R., Shan, J., Giles, F., Faderl, S., Verstovsek, S., Garcia-Manero, G., Rios, M.B., Kantarjian, H. Clin. Cancer Res. (2005)
- New targeted approaches in chronic myeloid leukemia. Cortes, J., Kantarjian, H. J. Clin. Oncol. (2005)
- Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cortes, J., O'Brien, S., Quintas, A., Giles, F., Shan, J., Rios, M.B., Talpaz, M., Kantarjian, H. Cancer (2004)
- Phase I study of bortezomib in refractory or relapsed acute leukemias. Cortes, J., Thomas, D., Koller, C., Giles, F., Estey, E., Faderl, S., Garcia-Manero, G., McConkey, D., Ruiz, S.L., Patel, G., Guerciolini, R., Wright, J., Kantarjian, H. Clin. Cancer Res. (2004)
- Natural history and staging of chronic myelogenous leukemia. Cortes, J. Hematol. Oncol. Clin. North Am. (2004)
- Investigational strategies in chronic myelogenous leukemia. Cortes, J.E., O'Brien, S.M., Giles, F., Alvarez, R.H., Talpaz, M., Kantarjian, H.M. Hematol. Oncol. Clin. North Am. (2004)
- Clonal evolution in chronic myelogenous leukemia. Cortes, J., O'Dwyer, M.E. Hematol. Oncol. Clin. North Am. (2004)
- Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Cortes, J., Albitar, M., Thomas, D., Giles, F., Kurzrock, R., Thibault, A., Rackoff, W., Koller, C., O'Brien, S., Garcia-Manero, G., Talpaz, M., Kantarjian, H. Blood (2003)
- Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Cortes, J.E., Talpaz, M., Giles, F., O'Brien, S., Rios, M.B., Shan, J., Garcia-Manero, G., Faderl, S., Thomas, D.A., Wierda, W., Ferrajoli, A., Jeha, S., Kantarjian, H.M. Blood (2003)
- Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Cortes, J., Ault, P., Koller, C., Thomas, D., Ferrajoli, A., Wierda, W., Rios, M.B., Letvak, L., Kaled, E.S., Kantarjian, H. Blood (2003)
- A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cortes, J., Kantarjian, H., Albitar, M., Thomas, D., Faderl, S., Koller, C., Garcia-Manero, G., Giles, F., Andreeff, M., O'Brien, S., Keating, M., Estey, E. Cancer (2003)
- Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Cortes, J., Giles, F., O'Brien, S., Thomas, D., Garcia-Manero, G., Rios, M.B., Faderl, S., Verstovsek, S., Ferrajoli, A., Freireich, E.J., Talpaz, M., Kantarjian, H. Blood (2003)
- Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cortes, J., Giles, F., O'Brien, S., Thomas, D., Albitar, M., Rios, M.B., Talpaz, M., Garcia-Manero, G., Faderl, S., Letvak, L., Salvado, A., Kantarjian, H. Cancer (2003)
- CMML: a biologically distinct myeloproliferative disease. Cortes, J. Curr. Hematol. Rep. (2003)
- Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Cortes, J. Clin. Lymphoma (2003)
- New agents in chronic myelogenous leukemia. Cortes, J., Giles, F. J. Natl. Compr. Canc. Netw (2003)
- Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cortes, J., Thomas, D., Rios, A., Koller, C., O'Brien, S., Jeha, S., Faderl, S., Kantarjian, H. Cancer (2002)
- High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cortes, J., Estey, E., O'Brien, S., Giles, F., Shen, Y., Koller, C., Beran, M., Thomas, D., Keating, M., Kantarjian, H. Cancer (2001)
- Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cortes, J., O'Brien, S., Loscertales, J., Kantarjian, H., Giles, F., Thomas, D., Koller, C., Keating, M. Cancer (2001)
